Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. ViroGates A/S
  6. News
  7. Summary
    VIRO   DK0061030574

VIROGATES A/S

(VIRO)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

SuPAR: An exciting biomarker of systemic chronic inflammation

08/27/2021 | 03:52am EDT

suPAR provides a more stable biomarker of systemic chronic inflammation than CRP or IL-6 and is less subject to the influence of acute infection and environmental exposures.

Exposure to adverse life experiences associates with increased morbidity and mortality from a range of diseases in later life. Growing evidence suggests that systemic inflammation may contribute to these relationships, with early childhood adversity and stressful life experiences in adulthood.

Higher suPAR levels predict poorer prognosis across conditions, accelerated biological aging, and mortality both in clinical and healthy populations. In sum, suPAR is recognized as a nonspecific marker of systemic chronic inflammation that is common to many inflammatory diseases and may serve as a marker of health risk in the general population.

Conclusion: suPAR is an exciting biomarker that may provide a more stable measure of systemic chronic inflammation and supplement more traditional markers of inflammation in the prediction of health risk.

Disclaimer

ViroGates A/S published this content on 26 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 August 2021 07:51:08 UTC.


ę Publicnow 2021
All news about VIROGATES A/S
10/25VIROGATES A/S : announces a new hospital as a clinical routine customer in Greece
AQ
10/25ViroGates A/S Announces New Hospital as Clinical Routine Customer in Greece
CI
10/21VIROGATES A/S : SuPAR is associated with risk for thromboembolic complications and mortali..
PU
10/14EVALUATION OF SUPAR LEVELS IN PATIEN : An observational cohort study
PU
09/17VIROGATES A/S : SuPAR measured using suPARnostic« TurbiLatex predicts critical illness and..
PU
09/06VIROGATES A/S : SAVE-MORE study on the effect of suPARnostic« guided anakinra treatment in..
AQ
09/03VIROGATES A/S : notification of transactions by persons discharging managerial responsibil..
AQ
08/27SUPAR : An exciting biomarker of systemic chronic inflammation
PU
08/24VIROGATES : Eagerly awaiting October
AQ
08/19VIROGATES ANNOUNCES ITS HALF-YEAR RE : Increasing clinical revenue and positive topline re..
AQ
More news
Financials
Sales 2020 5,35 M 0,84 M 0,84 M
Net income 2020 -18,7 M -2,92 M -2,92 M
Net cash 2020 33,5 M 5,23 M 5,23 M
P/E ratio 2020 -13,4x
Yield 2020 -
Capitalization 524 M 81,7 M 81,8 M
EV / Sales 2019 17,5x
EV / Sales 2020 41,3x
Nbr of Employees 14
Free-Float 47,9%
Chart VIROGATES A/S
Duration : Period :
ViroGates A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIROGATES A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Managers and Directors
Jakob Knudsen Chief Executive Officer
Mark Christian Hvidberg da Silva Chief Financial Officer
Lars Kongsbak Chairman
Jesper Eugen-Olsen Chief Scientific Officer
J÷rgen Axel Thorball Director
Sector and Competitors
1st jan.Capi. (M$)
VIROGATES A/S95.71%79
EXACT SCIENCES CORPORATION-29.07%16 106
GUARDANT HEALTH, INC.-11.13%11 603
INVITAE CORPORATION-31.98%6 181
BGI GENOMICS CO., LTD.-33.68%5 502
ADAPTIVE BIOTECHNOLOGIES CORPORATION-42.50%4 786